Humanized monoclonal antibodies to tumor necrosis factor–α are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 (“reversal”) leprosy reactions.
Journal Article. 2232 words. Illustrated.
Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology
Full text: subscription required